We are live on ! Find out more
INKT icon

MiNK Therapeutics
INKT

11 hedge funds and large institutions have $504K invested in MiNK Therapeutics in 2022 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 2 increasing their positions, 7 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.13% less ownership

Funds ownership: 0.23% → 0.11% (-0.13%)

56% less funds holding

Funds holding: 25 → 11 (-14)

71% less capital invested

Capital invested by funds: $1.76M → $504K (-$1.26M)

71% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 7

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 13

Holders
11
Holders Change
-14
Holders Change %
-56%
% of All Funds
0.19%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
2
Reduced
7
Closed
13
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
+$697
2
Fidelity Investments
Fidelity Investments
Massachusetts
+$396

Top Sellers

Rank Fund Capital Flow
1
SI
Sofinnova Investments
California
-$745K
2
Renaissance Technologies
Renaissance Technologies
New York
-$58K
3
State Street
State Street
Massachusetts
-$38K
4
Vanguard Group
Vanguard Group
Pennsylvania
-$23K
5
BlackRock
BlackRock
New York
-$20.7K
Name Holding Trade Value Shares
Change 		Change in
Stake
AG
1
Artal Group
Luxembourg
$408K – – –
BCM
2
Bridgeway Capital Management
Texas
$50K – – –
Geode Capital Management
3
Geode Capital Management
Massachusetts
$32K -$20.2K -1,072 -32%
BlackRock
4
BlackRock
New York
$10K -$20.7K -1,100 -62%
TRCT
5
Tower Research Capital (TRC)
New York
$2K -$2.21K -117 -52%
Fidelity Investments
6
Fidelity Investments
Massachusetts
$1K +$396 +21 +131%
Morgan Stanley
7
Morgan Stanley
New York
$1K +$697 +37 +411%
SI
8
Sofinnova Investments
California
– -$745K -33,100 Closed
Renaissance Technologies
9
Renaissance Technologies
New York
– -$58K -2,576 Closed
State Street
10
State Street
Massachusetts
– -$38K -1,678 Closed
Vanguard Group
11
Vanguard Group
Pennsylvania
– -$23K -1,035 Closed
New York State Common Retirement Fund
12
New York State Common Retirement Fund
New York
– -$18K -800 Closed
UBS Group
13
UBS Group
Switzerland
– -$9.61K -510 -95%
Bank of America
14
Bank of America
North Carolina
– -$3.77K -200 Closed
AIG
15
American International Group
New York
– -$2K -100 Closed
California State Teachers Retirement System (CalSTRS)
16
California State Teachers Retirement System (CalSTRS)
California
– -$2K -71 Closed
JP Morgan Chase
17
JP Morgan Chase
New York
– -$1.3K -69 -73%
Wells Fargo
18
Wells Fargo
California
– -$810 -43 -96%
Barclays
19
Barclays
United Kingdom
– -$1K -33 Closed
AB
20
Amalgamated Bank
New York
– -$1K -30 Closed
Citigroup
21
Citigroup
New York
– -$113 -6 -75%

INKT Hedge Fund Activity: Q2 2022 in Review

11 of the 5,937 institutional investors tracked by Wall St. Rank reported a position in MiNK Therapeutics (INKT) for Q2 2022, worth a combined $504K — down 71% from $1.76M a quarter earlier.

Sellers outnumbered buyers: 13 funds closed out of INKT and 0 opened new positions — a net loss of 13 holders — while 7 trimmed existing stakes and 2 added.

The largest buyer was Morgan Stanley, adding an estimated $697. The largest seller was Sofinnova Investments, exiting entirely with an estimated $745K sold.

  • 11 institutional investors held MiNK Therapeutics (INKT) as of Q2 2022, down from 25 in Q1 2022.
  • Funds reported $504K of MiNK Therapeutics stock for Q2 2022, down 71% quarter-over-quarter.
  • 0 funds opened new MiNK Therapeutics positions in Q2 2022 and 13 closed out, a net change of -13 holders.
  • The largest MiNK Therapeutics buyer in Q2 2022 was Morgan Stanley, an estimated $697 added.
  • The largest MiNK Therapeutics seller in Q2 2022 was Sofinnova Investments, an estimated $745K sold.

Based on aggregated 13F filings for Q2 2022.